Under Section 204 (of Title II, Division BB) of the Consolidated Appropriations Act, 2021 (CAA), insurance companies and employer-based health plans must submit information about prescription drugs and health care spending. This data submission is called the RxDC report. The Rx stands for prescription drug and the DC stands for data collection. The RxDC report isn't only about prescription drugs. It also collections information about spending on health care services and premium paid by members and employers.
The Centers for Medicare and Medicaid Services is collecting the RxDC report on behalf of the Departments of Health and Human Services, the Department of Labor, the Department of Treasury, and the Office of Personnel Management.
Primary Filing Resources
- RxDC reporting instructions (PDF)
- RxDC templates and data dictionary (ZIP)
- RxDC drug name and therapeutic class crosswalk (XLSX)
- RxDC data validations (XLSX)
- Frequently Asked Questions (PDF)
- Training Resource Directory (PDF)
- RxDC YouTube Playlist
- Federal Regulation
- RxDC HIOS Module User Manual (PDF)
- Click here to Submit your data in the CMS Enterprise Portal
If you want to receive an email alert when RxDC resources are updated, create a Registration for Technical Assistance Portal (REGTAP) account at https://regtap.cms.gov. REGTAP is also where you can register for training webinars.
What information do insurance companies and employers submit to CMS?
The CAA requires insurance companies and employer-based health plans to submit information about:
- Spending on prescription drugs and health care services
- Prescription drugs that account for the most spending
- Drugs that are prescribed most frequently
- Prescription drug rebates from drug manufacturers
- Premiums and cost-sharing that patients pay
How will this information be used?
The data submitted by insurance companies and employer-based health plans will help to:
- Identify major drivers of increases in prescription drug and health care spending
- Understand how prescription drug rebates impact premiums and out-of-pocket costs
- Promote transparency in prescription drug pricing
What information will be publicly released?
We will publish findings about prescription drug pricing trends and the impact of prescription drug rebates on patient out-of-pocket costs. You will be able to download the report from this page or from the websites of the Department of Labor or the Department of the Treasury.